Insider · CIK 0001787359

Tahir Misbah

Reports to the SEC for 2 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001787359

Forms 4 and 5

Insider transactions

47 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-02	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+40K sh	—	—	40,000
2026-03-02	MAZEMaze Therapeutics, Inc. · Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+20K sh	—	—	20,000
2025-09-02	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+325K sh	—	—	325,000
2025-07-23	IGM Biosciences, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−8,741 sh	$1.27	−$11.1K	170,061
2025-06-16	IGM Biosciences, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−1,522 sh	$1.20	−$1,825.182	178,802
2025-03-14	IGM Biosciences, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−7,329 sh	$1.23	−$9,014.67	180,324
2024-12-16	IGM Biosciences, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−1,708 sh	$7.48	−$12.8K	187,653
2024-11-18	IGM Biosciences, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+66.7K sh	—	—	189,361
2024-09-13	IGM Biosciences, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−1,487 sh	$11.54	−$17.2K	122,694
2024-07-19	IGM Biosciences, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+33.1K sh	—	—	121,959
2024-07-19	IGM Biosciences, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+2,222 sh	—	—	124,181
2024-07-19	IGM Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	CHIEF FINANCIAL OFFICER	DDisposition to Issuer	−55K sh	—	—	0
2024-07-19	IGM Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	CHIEF FINANCIAL OFFICER	DDisposition to Issuer	−40K sh	—	—	0
2024-06-14	IGM Biosciences, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−1,570 sh	$7.58	−$11.9K	88,848
2024-03-14	IGM Biosciences, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−2,543 sh	$10.17	−$25.9K	90,418
2024-03-13	IGM Biosciences, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−2,897 sh	$9.88	−$28.6K	92,961
2024-03-12	IGM Biosciences, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+46.3K sh	—	—	95,858
2024-03-12	IGM Biosciences, Inc.Stock Option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+92.5K sh	—	—	92,500
2023-11-27	IGM Biosciences, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−1,337 sh	$5.06	−$6,764.15	49,608
2023-11-15	IGM Biosciences, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+234 sh	$11.71	+$2,740.14	50,945
2023-05-23	IGM Biosciences, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−1,244 sh	$12.30	−$15.3K	50,726
2023-05-23	IGM Biosciences, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−15 sh	$13.01	−$195.075	50,711
2023-05-15	IGM Biosciences, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+398 sh	$11.71	+$4,660.58	51,970
2023-04-04	IGM Biosciences, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+26.3K sh	—	—	51,572
2023-04-04	IGM Biosciences, Inc.Stock Option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+52.5K sh	—	—	52,500
2023-03-14	IGM Biosciences, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−1,768 sh	$18.73	−$33.1K	25,322
2022-12-19	IGM Biosciences, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−3,801 sh	$20.00	−$76K	27,090
2022-12-16	IGM Biosciences, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−1,468 sh	$18.77	−$27.6K	31,706
2022-12-16	IGM Biosciences, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−815 sh	$19.36	−$15.8K	30,891
2022-11-23	IGM Biosciences, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−600 sh	$21.38	−$12.8K	33,451
2022-11-23	IGM Biosciences, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−277 sh	$21.99	−$6,091.618	33,174
2022-11-15	IGM Biosciences, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+353 sh	$12.84	+$4,532.52	34,051
2022-05-26	IGM Biosciences, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−950 sh	$17.10	−$16.2K	33,698
2022-05-13	IGM Biosciences, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+391 sh	$12.38	+$4,840.58	34,648
2022-03-15	IGM Biosciences, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+6,084 sh	—	—	34,257
2022-03-12	IGM Biosciences, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+12.5K sh	—	—	28,173
2022-03-12	IGM Biosciences, Inc.Stock Option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+75K sh	—	—	75,000
2021-11-15	IGM Biosciences, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+86 sh	$50.99	+$4,385.14	5,673
2021-11-15	IGM Biosciences, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+10K sh	—	—	15,673
2021-05-14	IGM Biosciences, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+45 sh	$45.90	+$2,065.5	5,587
2021-03-05	IGM Biosciences, Inc.M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	+2,750 sh	$1.39	+$3,822.5	5,542
2021-03-05	IGM Biosciences, Inc.Stock Option (right to buy)M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	−2,750 sh	—	—	120,097
2021-02-19	IGM Biosciences, Inc.Stock Option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+40K sh	—	—	40,000
2020-12-21	IGM Biosciences, Inc.M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	+2,750 sh	$1.39	+$3,822.5	2,792
2020-12-21	IGM Biosciences, Inc.Stock Option (right to buy)M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	−2,750 sh	—	—	122,847
2020-11-13	IGM Biosciences, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+42 sh	$45.45	+$1,908.9	42
2020-02-05	IGM Biosciences, Inc.Stock Option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+55K sh	—	—	55,000

Recent filings

Accepted (ET)
Mar 34
Tahir Misbah0001787359-26-000002
SEC(opens sec.gov)
Sep 24
Tahir Misbah0001415889-25-023463
SEC(opens sec.gov)
Jul 254
Tahir Misbah0001415889-25-020311
SEC(opens sec.gov)
Jun 204
Tahir Misbah0001415889-25-017915
SEC(opens sec.gov)
Mar 184
Tahir Misbah0001415889-25-008520
SEC(opens sec.gov)
Dec 184
Tahir Misbah0001415889-24-029775
SEC(opens sec.gov)
Nov 204
Tahir Misbah0001415889-24-027363
SEC(opens sec.gov)
Sep 174
Tahir Misbah0001415889-24-023586
SEC(opens sec.gov)
Jul 234
Tahir Misbah0001415889-24-020004
SEC(opens sec.gov)
Jun 184
Tahir Misbah0001415889-24-017499
SEC(opens sec.gov)
Mar 154
Tahir Misbah0001415889-24-008169
SEC(opens sec.gov)
Mar 144
Tahir Misbah0001415889-24-008054
SEC(opens sec.gov)
Nov 294
Tahir Misbah0001209191-23-056944
SEC(opens sec.gov)

Companies

Address

C/O MAZE THERAPEUTICS, INC. 171 OYSTER POINT BOULEVARD, SUITE 300

SOUTH SAN FRANCISCO, CA, 94080